Literature DB >> 14722208

Access to bone densitometry increases general practitioners' prescribing for osteoporosis in steroid treated patients.

A L Dolan1, E Koshy, M Waker, C M Goble.   

Abstract

BACKGROUND: Availability of access to bone densitometry in the UK varies widely and there are concerns as to appropriate prescribing. Studies suggest inadequate use of osteoporosis prophylaxis in steroid users, despite recent guidelines.
OBJECTIVE: To examine in a case-control study whether access to bone densitometry affects GPs' osteoporosis prescribing in high risk steroid users.
METHOD: 10 general practices were included, five from primary care trusts (PCTs) with access to bone densitometry and five with limited access. Patients receiving prednisolone for >3 months were identified by database search. Patients receiving no prophylaxis other than calcium and vitamin D (Ca/D) were subsequently included. Appropriate patients in five practices were offered DXA scan (cases) and review. Patients in practices without access to scans (controls) were reviewed. GPs' opinions leading to treatment were sought by structured questionnaire.
RESULTS: 132 (0.12%) patients were receiving prednisolone for >/=3 months, but no osteoporosis prophylaxis other than Ca/D. Pre-study prophylaxis ranged from 18 to 36%. Of 48 patients scanned, 21 (44%) were abnormal and 18 (38%) received new treatment. 13/44 (30%) controls received new treatment. 10/21 (48%) with abnormal scans started a bisphosphonate, compared with 7/44 (16%) controls (RR = 3, p = 0.004). No difference in risk factors for fracture was found in treated and untreated controls.
CONCLUSIONS: GPs were three times more likely to start potent osteoporosis treatment after abnormal scans than GPs relying on clinical information. In practice, risk factors were not adequately assessed. Database searches may identify patients needing osteoporosis prophylaxis; however, DXA enables more appropriate patient treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722208      PMCID: PMC1754894          DOI: 10.1136/ard.2003.006130

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  17 in total

1.  Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds.

Authors:  J A Kanis; O Johnell; A Oden; A Dawson; C De Laet; B Jonsson
Journal:  Osteoporos Int       Date:  2001-12       Impact factor: 4.507

2.  Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study.

Authors:  L J Walsh; C A Wong; M Pringle; A E Tattersfield
Journal:  BMJ       Date:  1996-08-10

3.  Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Authors:  S Cohen; R M Levy; M Keller; E Boling; R D Emkey; M Greenwald; T M Zizic; S Wallach; K L Sewell; B P Lukert; D W Axelrod; A A Chines
Journal:  Arthritis Rheum       Date:  1999-11

Review 4.  The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.

Authors:  T P van Staa; H G M Leufkens; C Cooper
Journal:  Osteoporos Int       Date:  2002-10       Impact factor: 4.507

5.  Public health impact of adverse bone effects of oral corticosteroids.

Authors:  T P van Staa; L Abenhaim; C Cooper; B Zhang; H G Leufkens
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

6.  Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice.

Authors:  B Gudbjornsson; U I Juliusson; F V Gudjonsson
Journal:  Ann Rheum Dis       Date:  2002-01       Impact factor: 19.103

7.  Risk of new vertebral fracture in the year following a fracture.

Authors:  R Lindsay; S L Silverman; C Cooper; D A Hanley; I Barton; S B Broy; A Licata; L Benhamou; P Geusens; K Flowers; H Stracke; E Seeman
Journal:  JAMA       Date:  2001-01-17       Impact factor: 56.272

8.  Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids.

Authors:  A Verstraeten; J Dequeker
Journal:  Ann Rheum Dis       Date:  1986-10       Impact factor: 19.103

Review 9.  Management of corticosteroid-induced osteoporosis. UK Consensus Group Meeting on Osteoporosis.

Authors:  R Eastell
Journal:  J Intern Med       Date:  1995-05       Impact factor: 8.989

10.  Steroid induced osteoporosis: an opportunity for prevention?

Authors:  I D Peat; S Healy; D M Reid; S H Ralston
Journal:  Ann Rheum Dis       Date:  1995-01       Impact factor: 19.103

View more
  3 in total

Review 1.  Systematic review of trends in prophylaxis of corticosteroid-induced osteoporosis: the need for standard audit guidelines.

Authors:  M Duyvendak; M Naunton; E N van Roon; G A W Bruyn; J R B J Brouwers
Journal:  Osteoporos Int       Date:  2008-07-16       Impact factor: 4.507

2.  Prescription of anti-osteoporosis drugs during 2004-2007-a nationwide register study in Norway.

Authors:  Helene M Devold; Gia Man Doung; Aage Tverdal; Kari Furu; Haakon E Meyer; Jan A Falch; Anne Johanne Sogaard
Journal:  Eur J Clin Pharmacol       Date:  2009-11-07       Impact factor: 2.953

3.  Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate.

Authors:  A Bitto; B P Burnett; F Polito; R M Levy; H Marini; V Di Stefano; N Irrera; M A Armbruster; L Minutoli; D Altavilla; F Squadrito
Journal:  Br J Pharmacol       Date:  2009-03-19       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.